Cold type haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:08 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cold type haemolytic anaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Povetacicept for Patients with Autoimmune Cytopenias (wAIHA, CAD, ITP) https://clinicaltrials.eu/trial/study-on-povetacicept-for-patients-with-autoimmune-cytopenias-waiha-cad-itp/ Wed, 29 Apr 2026 14:30:11 +0000 https://clinicaltrials.eu/trial/study-on-povetacicept-for-patients-with-autoimmune-cytopenias-waiha-cad-itp/ This clinical trial is focused on studying autoimmune cytopenias, which are conditions where the immune system mistakenly attacks and destroys blood cells. The specific types of autoimmune cytopenias being studied include warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), and immune thrombocytopenia (ITP). The treatment being tested in this study is called Povetacicept Injection, also known by its code name ALPN-303. This medication is given as a solution for injection under the skin.

The purpose of the study is to evaluate the safety and tolerability of Povetacicept in individuals with these autoimmune conditions. Participants in the study will receive Povetacicept and will be monitored to assess how their bodies respond to the treatment. The study will look at various factors, including any side effects that may occur and how the medication affects the participants’ health over time.

Throughout the study, participants will receive regular check-ups and assessments to ensure their well-being and to gather information on the effectiveness of the treatment. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. This trial aims to provide valuable insights into the potential benefits and risks of using Povetacicept for treating autoimmune cytopenias.

]]> Study on Zanubrutinib for Patients with Primary Cold Agglutinin Disease https://clinicaltrials.eu/trial/study-on-zanubrutinib-for-patients-with-primary-cold-agglutinin-disease/ Wed, 29 Apr 2026 14:30:10 +0000 https://clinicaltrials.eu/trial/study-on-zanubrutinib-for-patients-with-primary-cold-agglutinin-disease/ This clinical trial is focused on studying a condition known as Cold Agglutinin Disease (CAD). CAD is a rare blood disorder where the immune system mistakenly attacks and destroys red blood cells, especially in cold temperatures. The trial will investigate the effects of a medication called Zanubrutinib, which is a type of drug known as a tyrosine kinase inhibitor. This medication is taken orally in the form of a capsule.

The purpose of the study is to evaluate how effective Zanubrutinib is in treating patients with primary CAD. Participants in the study will receive Zanubrutinib over a series of 6 treatment cycles. During these cycles, the response of the disease to the medication will be closely monitored. The study aims to see if Zanubrutinib can help reduce the symptoms of CAD and improve the overall health of the participants.

Throughout the study, various aspects of the participants’ health will be assessed, including changes in blood parameters and symptoms related to CAD. The study will also look at how the treatment affects the quality of life and fatigue levels of the participants. The trial is designed to provide valuable information on the potential benefits of Zanubrutinib for individuals living with CAD.

]]>